


Amendments to the Claims:


1. (Original) A compound of the formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B independently represent CH₂ or O, with the proviso that A and B are not simultaneously O;

Cy represents one of the following



optionally substituted by one to three groups selected from hydroxy, halogen, C₁₋₆alkyl,

C₁₋₆alkoxy, C₁₋₆haloalkyl, C₁₋₆alkylamino and amino;

R¹ and R² are independently selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy,

C₁₋₆haloalkyl and C₃₋₈cycloalkyl;

n represents an integer from 0-4;

X is hydrogen, hydroxy, halogen or C₁₋₆alkoxy;

Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl;

Z is CH or N; and

p represents an integer from 0-5 when Z is CH or 0-4 when Z is N,

when p represents 2 or more, two of R²s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring.

2. (Currently Amended) A compound according to claim 1 ~~where~~ wherein A and B represent carbon atoms.
3. (Currently Amended) A compound according to claim 1 ~~where~~ wherein A represents O and B represents C.
4. (Currently Amended) A compound according to claim 1 ~~where~~ wherein A represents C and B represents O.
5. (Currently Amended) A compound according to ~~any one of claims 1 to 4~~ where Cy is selected from optionally further substituted 4-hydroxyphenyl, 1H-pyrazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazole-6-yl and 2-hydroxy-5-pyridyl.
6. (Currently Amended) A compound according to ~~any one of claims 1 to 5 where~~ wherein Cy represents 4-hydroxyphenyl, optionally further substituted by fluoro or methyl.
7. (Currently Amended) A compound according to ~~any one of claims 1 to 6 where~~ wherein n represents 0.

8. (Currently Amended) A compound according to ~~any one of claims 1 to 7~~ wherein R^2 represents methoxy, chloro, fluoro or methyl.

9. (Currently Amended) A compound according to ~~any one of claims 1 to 8~~ wherein p represents 0-2.

10. (Currently Amended) A compound according to ~~any one of claims 1 to 9~~ wherein X is hydrogen or hydroxy.

11. (Currently Amended) A compound according to ~~any one of claims 1 to 10~~ wherein Y is selected from methylene, oxyethyleneoxy, oxymethylene, methyleneoxy, methyleneoxymethylene, ethyleneoxy, oxyethylene and oxy.

12. (Currently Amended) A compound according to ~~any one of claims 1 to 11~~ wherein Y is *para* located to and in a *trans* configuration to X.

13. (Currently Amended) A compound of formula (I) selected from the group consisting of:

4-Hydroxy-*N*-{[*cis*-4-(phenoxy)methyl]cyclohexyl}methyl}benzamide;
 4-Hydroxy-*N*-({*cis*-4-[(4-methoxyphenoxy)methyl]cyclohexyl}methyl)benzamide;
N-{[*cis*-4-(Benzyloxy)cyclohexyl]methyl}-4-hydroxybenzamide;
N-({*cis*-4-[(4-Chlorobenzyl)oxy]cyclohexyl}methyl)-4-hydroxybenzamide;
N-({*cis*-4-[(3-Chlorobenzyl)oxy]cyclohexyl}methyl)-4-hydroxybenzamide;
 4-Hydroxy-*N*-{[*cis*-4-(4-methoxyphenoxy)cyclohexyl]methyl}benzamide;
N-{[*cis*-4-(4-Chlorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;
 4-Hydroxy-*N*-{[1-hydroxy-4-(phenoxy)methyl]cyclohexyl}methyl}benzamide;
N-({*trans*-4-[(4-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(3-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(2-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(2,6-Difluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(3,5-Difluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(3-Chlorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(4-Chlorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
 4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[(2-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[(3-methylphenoxy)methyl]cyclohexyl)methyl}benzamide;
 4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[(4-methylphenoxy)methyl]cyclohexyl)methyl}benzamide;
N-({*trans*-4-[(Benzyloxy)methyl]-1-hydroxycyclohexyl)methyl}-4-hydroxybenzamide;
N-[({*trans*-4-[(2-Fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[({*trans*-4-[(4-Fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
 4-Hydroxy-*N*-[({*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl)methyl}benzamide;
N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl}-4-hydroxybenzamide;
N-({*trans*-4-[2-(3-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl}-4-hydroxybenzamide;
N-({*trans*-4-[2-(4-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl}-4-hydroxybenzamide;
N-[({*trans*-4-(Benzyloxy)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[({*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[({*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[({*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl}-3-fluoro-4-hydroxybenzamide;
N-[({*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl}-3-fluoro-4-hydroxybenzamide;
 (+)-4-hydroxy-*N*-[({5*S*-(phenoxymethyl)tetrahydro-2*H*-pyran-2*S*-yl)methyl}benzamide;
 (-)-4-hydroxy-*N*-[({5*R*-(phenoxymethyl)tetrahydro-2*H*-pyran-2*R*-yl)methyl}benzamide;
 4-hydroxy-*N*-[({5*S*-(benzyloxymethyl)tetrahydro-2*H*-pyran-2*S*-yl)methyl}benzamide;
 4-hydroxy-*N*-[({5*R*-(benzyloxymethyl)tetrahydro-2*H*-pyran-2*R*-yl)methyl}benzamide;
 (-)-4-Hydroxy-*N*-[({(3*R*,6*S*)-6-(phenoxymethyl)tetrahydro-2*H*-pyran-3-yl)methyl}benzamide;
 (+)-4-Hydroxy-*N*-[({(3*S*,6*R*)-6-(phenoxymethyl)tetrahydro-2*H*-pyran-3-yl)methyl}benzamide;
N-({*trans*-4-[(2-Fluorobenzyl)oxy]-1-hydroxycyclohexyl)methyl}-4-hydroxybenzamide;
 3-Fluoro-*N*-({*trans*-4-[2-(2-fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl}-4-hydroxybenzamide;
trans - *N*-[({4-(4-chlorophenoxy)cyclohexyl)methyl}-3-fluoro-4-hydroxybenzamide;
cis- *N*-[({4-(4-chlorophenoxy)cyclohexyl)methyl}-3-fluoro-4-hydroxybenzamide;
N-[({*cis*-4-(4-Fluorophenoxy)cyclohexyl)methyl]-4-hydroxybenzamide;
 3-Fluoro-*N*-[({*cis*-4-(4-fluorophenoxy)cyclohexyl)methyl]-4-hydroxybenzamide;
N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl}-1*H*-pyrazole-4-carboxamide;
 4-hydroxy-*N*-[({*cis*-4-(2-phenylethoxy)cyclohexyl)methyl}benzamide;
 2-fluoro-4-hydroxy-*N*-[({*trans*-1-hydroxy-4-(phenoxymethyl)cyclohexyl)methyl}benzamide;
N-({*trans*-4-[(benzyloxy)methyl]-1-hydroxycyclohexyl)methyl}-3-fluoro-4-hydroxybenzamide;
N-({*cis*-4-[(Benzyloxy)methyl]cyclohexyl)methyl}-4-hydroxybenzamide

3-Fluoro-4-hydroxy-*N*-{[(*trans*-1-hydroxy-4-(phenoxyethyl)cyclohexyl)methyl]}benzamide;
3-Fluoro-4-hydroxy-*N*-{[(*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl)methyl]}benzamide;
3-Fluoro-*N*-{[(*trans*-4-[(4-fluorobenzyl)oxy]methyl)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-Fluoro-*N*-{[(*trans*-4-[(2-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-Fluoro-*N*-{[(*trans*-4-[(4-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
4-Hydroxy-*N*-{[(*trans*-1-hydroxy-4-[(5-methylpyridin-2-yl)oxy]methyl)cyclohexyl)methyl]}benzamide;
N-{[(*trans*-4-Benzyl-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-fluoro-*N*-{[(*trans*-4-[(2-fluorobenzyl)oxy]methyl)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
6-Hydroxy-*N*-{[(*cis*-4-(2-phenethoxy)cyclohexyl)methyl]}nicotinamide;
N-{[(*cis*-4-(2-Phenylethoxy)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(*cis*-4-(Phenoxyethyl)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(*cis*-4-(2-Phenoxyethyl)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(*cis*-4-[(3-Fluorophenoxy)methyl]cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(*cis*-4-[(4-Fluorophenoxy)methyl]cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(2*R*,5*R*)-5-[(4-Fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(*cis*-4-(4-Methoxybenzyl)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
3-Amino-*N*-{[(*cis*-4-benzylcyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(2*R*,5*R*)-5-[(4-Chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
3-Amino-*N*-{[(2*R*,5*R*)-5-[(4-fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
3-Amino-*N*-{[(2*R*,5*R*)-5-[(4-chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide; and
3-Amino-*N*-{[(2*R*,5*R*)-5-[(4-ethylphenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

14. (Currently Amended) A pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in ~~any one of claims 1 to 13~~, together with a pharmaceutically acceptable excipient.

15. (Currently Amended) A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in ~~any one of claims 1 to 14~~, for use as a medicament.

16. (Cancel)

17. (Cancel)

18. (Currently Amended) A method of treatment of a mammal, including a human being, to treat a disease for which an NMDA NR2B antagonist is indicated, including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof, as defined in ~~any one of claims 1 to 13 and 14, respectively~~.

19. (Currently Amended) A method according to claim 18 ~~where~~wherein the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.

20. (Currently Amended) A combination of a compound of the formula (I), as defined in ~~any one of claims 1 to 13~~, and another pharmacologically active agent.